• Explore /
  • Poster
  • / VOICE trial: Final results from multicenter phaseII study of assessment of clinical efficiency and safety in capecitabine plus intermittent oxaliplatin together with bevacizumab as first-line therapy for patients with advanced colorectal cancer.

VOICE trial: Final results from multicenter phaseII study of assessment of clinical efficiency and safety in capecitabine plus intermittent oxaliplatin together with bevacizumab as first-line therapy for patients with advanced colorectal cancer.

Abstract Poster

Authors

null

Chihiro Kosugi

Teikyo University Chiba Medical Center, Ichihara, Japan

Chihiro Kosugi , Keiji Koda , Tadamichi Denda , Keiichiro Ishibashi , Hideyuki Ishida , Kazuhiro Seike , Naoto Sakata , Shinji Yanagisawa , Akinari Miyazaki , Wataru Takayama , Naoto Koike , Hisahiro Matsubara , Masato Yamazaki , Hiroaki Shimizu , Kiyohiko Shuto , Mikito Mori , Kazuo Narushima

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

UMIN000005732

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr 740)

DOI

10.1200/JCO.2018.36.4_suppl.740

Abstract #

740

Poster Bd #

J6

Abstract Disclosures

Similar Posters

First Author: Hitoshi Ojima

First Author: Makio Gamoh

First Author: Patricio Eduardo Yanez

First Author: Xin Qu